Garon, Edward BEdward BGaronLu, ShunShunLuGoto, YasushiYasushiGotoDe Marchi, PedroPedroDe MarchiPaz-Ares, LuisLuisPaz-AresSpigel, David RDavid RSpigelThomas, MichaelMichaelThomasCHIH-HSIN YANGArdizzoni, AndreaAndreaArdizzoniBarlesi, FabriceFabriceBarlesiOrlov, SergeySergeyOrlovYoshioka, HiroshigeHiroshigeYoshiokaMountzios, GiannisGiannisMountziosKhanna, SadhviSadhviKhannaBossen, ClaudiaClaudiaBossenCarbini, MarianaMarianaCarbiniTurri, SabineSabineTurriMyers, AndreaAndreaMyersCho, Byoung ChulByoung ChulCho2024-03-282024-03-282024-01-100732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/641512Effective treatments for resectable non-small-cell lung cancer (NSCLC) are limited and relapse rates are high. The interleukin (IL)-1β pathway has been linked with tumor development and progression, including in the Canakinumab Anti-Inflammatory Thrombosis Outcomes cardiovascular study in which IL-1β pathway inhibition with canakinumab reduced lung cancer incidence and mortality in an exploratory analysis.en[SDGs]SDG3journal article10.1200/JCO.23.00910377884122-s2.0-85181760525https://api.elsevier.com/content/abstract/scopus_id/85181760525